00:00In the last four years we have had a revolution in the treatment of non-oxygen lymphomas,
00:09in particular in receding and receding lymphomas, where the old chemo-therapeutic or trabeontological
00:16treatment gave very poor results. These new drugs are immunotherapies in particular,
00:23and in particular the aim is to reactivate the lymphocytes of the patient himself, bringing
00:28them to engineering in certain laboratories and then re-infusing it, or specific antibodies,
00:33so-called bi-specific, which aim to activate the same lymphocytes of the patient himself,
00:39with an address then on a particular antigen that the tumor cells have. With these treatments
00:45we have obtained results far superior to those we obtained with the old
00:51chemotherapy and with a better quality of life of the patient. You imagine a single infusion or
00:57infusion of an antibody compared to chemotherapy, transplant, recovery, hair loss, etc.
Comments